Compete with Chia Tai Tianqing and Yangzijiang for another Chengdu pharmaceutical company to disrupt antidepressants

Pharmaceutical Network September 23rd, September 22nd, CDE official website shows that Chengdu Kanghong Pharmaceuticals' hydrobromobromohitine tablet imitation 4 categories of listing applications were accepted.
meters of intranet data show that in 2019, China's public medical institutions terminal voxelstin tablet sales of more than 30 million yuan, production enterprises only Lingbei one.
Prior to this, the product Yangzijiang to imitation 3 categories, Zhengda Tianqing Pharmaceutical Group and Chengdu Beit Pharmaceuticals to copy 4 categories of submitted applications for listing, in the review and approval (in the drug review center).
hydrobromobromoxitin tablets are used to treat depression in adults.
November 2017, the hydrobrominate vulcanization tablets (commodity name: Xinda Yue) developed by The Danish company Lingbei were approved for listing by the State Drug Administration.
source: MiNet one-click search Minet data show that in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal sales of vulcan tablets, although only more than 30 million yuan, but the growth rate is staggering, up more than 700% year-on-year, manufacturers only Lingbei.
Source: MED2.0 China Drug Review Database, before the product Yangzijiang to copy 3 categories, Zhengda Tianqing Pharmaceutical Group and Chengdu Beit Pharmaceuticals to copy 4 categories to submit a listing application in the review and approval (in the drug review center).
from the date of the contractor, Yangzijiang's time is the earliest.
.